

Summary of Indications for Use:

DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes. Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.

There are no known contraindications.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in children or pregnant or lactating women. Risks can include transient pain, swelling and/or stiffness at the injection site.

Full prescribing information can be found in product labeling, or at www.durolane.com.

Bioventus Coöperatief U.A.
Taurusavenue 31
2132 LS Hoofddorp
The Netherlands

Customer Care (tff)
T (UK): 0800 05 16 384
T (IR): 1800 552 197
E: customercare-international@bioventusglobal.com

www.durolane.com
www.BioventusGlobal.com



DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

© 2017 Bioventus LLC. SMK-002094 05/17